Cabotegravir
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Cabotegravir: From HIV-1 Infection (Antiretroviral Use) to Rheumatoid Arthritis
One-Sentence Summary
Cabotegravir is an HIV-1 integrase strand transfer inhibitor, marketed in Singapore as oral tablets and long-acting injectable suspensions. The TxGNN model predicts it may be effective for rheumatoid arthritis, but no clinical trials and no publications currently support this prediction. The prediction rests on computational output alone, so it should be treated as a hypothesis only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV-1 infection (antiretroviral; the approved indication text is not recorded in the Singapore licence data) |
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 99.45% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for this drug is not available in the data compiled for this report. Cabotegravir is known as an HIV-1 integrase strand transfer inhibitor. It blocks viral DNA from integrating into the host genome, which is an antiviral mechanism.
Rheumatoid arthritis is driven by autoimmune inflammation involving pathways such as TNF, IL-6 and JAK-STAT signalling. No plausible link between integrase inhibition and these pathways has been established. The high TxGNN score most likely reflects the structure of the knowledge graph rather than demonstrated biology, and no supporting trial, publication or mechanistic study was found.
Other top-ranked predictions are similarly unsupported. They include sclerosing cholangitis, bronchitis, diabetic retinopathy (including the severe non-proliferative form) and several ultra-rare genetic disorders. All of them are L5 (model prediction only), with scores of about 97.8% to 99.2%, and all carry a Hold recommendation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16541P | VOCABRIA Film-Coated Tablets 30 mg | Tablet, film coated | Not recorded in the licence data |
| SIN16543P | VOCABRIA Prolonged-Release Suspension for Injection 400 mg/2 mL | Injection, suspension | Not recorded in the licence data |
| SIN16542P | VOCABRIA Prolonged-Release Suspension for Injection 600 mg/3 mL | Injection, suspension | Not recorded in the licence data |
All three licences are valid single-ingredient products. Available routes are oral and injectable.
Safety Considerations
- Drug Interactions: Seven moderate-level interactions were identified, all with polyvalent-cation antacids and buffering agents:
- Calcium carbonate
- Aluminium hydroxide
- Magnesium carbonate
- Magnesium hydroxide
- Magnesium oxide
- Sodium bicarbonate
- Sodium citrate
For other safety information, including warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for rheumatoid arthritis is supported only by a computational score (L5). There are no clinical trials, no publications and no established mechanistic link to rheumatoid arthritis pathophysiology. Cabotegravir's antiviral mechanism gives no obvious reason to expect an effect on autoimmune joint inflammation.
To proceed, the following is needed:
- Mechanism of action data (DrugBank) and an analysis of any plausible link to rheumatoid arthritis pathways
- Package insert warnings and contraindications from the HSA website, to allow safety screening
- Preclinical or in vitro evidence (for example, effects on inflammatory signalling in relevant models)
- A literature and trial registry search specific to cabotegravir and rheumatoid arthritis
- Assessment of route compatibility. Long-acting injectable and oral forms are available, but the required route for rheumatoid arthritis has not been defined.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.